[HTML][HTML] Aggressive pituitary tumors and pituitary carcinomas
SMC De Sousa, AI McCormack - Endotext [Internet], 2022 - ncbi.nlm.nih.gov
Aggressive pituitary tumors (APT) refer to pituitary adenomas exhibiting radiological
invasiveness and an unusually rapid tumor growth rate, or clinically relevant tumor growth …
invasiveness and an unusually rapid tumor growth rate, or clinically relevant tumor growth …
[HTML][HTML] The epidemiology of aggressive pituitary tumors (and its challenges)
OM Dekkers, N Karavitaki, AM Pereira - Reviews in Endocrine and …, 2020 - Springer
Pituitary tumors are not rare if prevalence rates from autopsy or radiological series are
considered; approximately 0.5% of all pituitary adenomas will come to medical attention …
considered; approximately 0.5% of all pituitary adenomas will come to medical attention …
Definition and diagnosis of aggressive pituitary tumors
L Kasuki, G Raverot - Reviews in Endocrine and Metabolic Disorders, 2020 - Springer
Pituitary adenomas are considered benign tumors, but approximately 10% of them can have
an aggressive behavior and more rarely (0.2%) can present metastasis, being classified as …
an aggressive behavior and more rarely (0.2%) can present metastasis, being classified as …
Nonfunctioning pituitary adenoma recurrence and its relationship with sex, size, and hormonal immunohistochemical profile
Background Tumor recurrence or incomplete resection in nonfunctioning pituitary adenomas
(NFPAs) is relatively common. However, predictive factors of tumor recurrence in NFPAs are …
(NFPAs) is relatively common. However, predictive factors of tumor recurrence in NFPAs are …
Non-functioning pituitary adenomas: growth and aggressiveness
KA Øystese, JA Evang, J Bollerslev - Endocrine, 2016 - Springer
Pituitary adenomas (PAs) are common, comprising approximately one third of all intracranial
tumors. Non-functioning pituitary adenomas (NFPAs) are the most common PAs. Although …
tumors. Non-functioning pituitary adenomas (NFPAs) are the most common PAs. Although …
[HTML][HTML] Emerging and novel treatments for pituitary tumors
A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior,
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …
showing resistance to treatment and/or multiple recurrences in spite of the optimal use of …
Congress of neurological surgeons systematic review and evidence-based guideline for the management of patients with residual or recurrent nonfunctioning pituitary …
BACKGROUND: Despite the advancement of microsurgical and endoscopic techniques,
some nonfunctioning pituitary adenomas (NFPAs) can be difficult to cure. Tumor recurrence …
some nonfunctioning pituitary adenomas (NFPAs) can be difficult to cure. Tumor recurrence …
Non-functioning pituitary adenomas
Y Greenman, N Stern - Best practice & research Clinical endocrinology & …, 2009 - Elsevier
Non-functioning pituitary tumours are mostly of gonadotroph cell origin and are devoid of
humoral hypersecretory syndromes. They are usually large at the time of diagnosis …
humoral hypersecretory syndromes. They are usually large at the time of diagnosis …
Long‐term follow‐up of a large prospective cohort of patients with nonfunctioning pituitary adenomas: the outcome of a conservative management policy
MJ Levy, IJ Robertson, N Khalk, S Vitello… - Clinical …, 2018 - Wiley Online Library
Objective To assess the clinical outcome of a strategy of conservative monitoring of patients
with nonfunctioning pituitary adenomas (NFPA) after pituitary surgery and in patients without …
with nonfunctioning pituitary adenomas (NFPA) after pituitary surgery and in patients without …
Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers
M Tampourlou, G Ntali, S Ahmed, W Arlt… - The Journal of …, 2017 - academic.oup.com
Context: Despite the major risk of regrowth of clinically nonfunctioning pituitary adenomas
(CNFAs) after primary treatment, systematic data on the probability of further tumor …
(CNFAs) after primary treatment, systematic data on the probability of further tumor …